Vascular MedicinePub Date : 2025-08-22DOI: 10.1177/1358863X251363530
Mette Søgaard, Bernard Dennis, Anette Arbjerg Højen, Carlos Mena-Hurtado, Kim G Smolderen
{"title":"A call for patient involvement in peripheral artery disease research priority setting.","authors":"Mette Søgaard, Bernard Dennis, Anette Arbjerg Højen, Carlos Mena-Hurtado, Kim G Smolderen","doi":"10.1177/1358863X251363530","DOIUrl":"https://doi.org/10.1177/1358863X251363530","url":null,"abstract":"","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"1358863X251363530"},"PeriodicalIF":3.3,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144971009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Effect of balloon angioplasty on inframalleolar stenosis in patients with chronic limb-threatening ischemia.","authors":"Riho Suzuki, Shuko Iwata, Yuichiro Hosoi, Yuki Tanaka, Michinao Tan, Katsumi Horiuchi, Yutaka Dannoura, Takao Makino, Hisashi Yokoshiki","doi":"10.1177/1358863X251361386","DOIUrl":"https://doi.org/10.1177/1358863X251361386","url":null,"abstract":"<p><strong>Background: </strong>Although there are reports on angioplasty for inframalleolar (IM) occluded lesions in chronic limb-threatening ischemia (CLTI), the clinical outcomes specific to the IM stenotic lesions remain unclear. This study evaluated the effect of balloon angioplasty for IM stenotic lesions on the clinical outcomes of patients with CLTI.</p><p><strong>Methods: </strong>This is a multicenter, retrospective, nonrandomized observational study. We retrospectively analyzed 194 patients with CLTI who underwent endovascular therapy for infrapopliteal (IP) lesions with IM stenotic lesions distal to the target IP lesion between November 2017 and August 2022. Angioplasty for IM stenotic lesions was performed in 99 patients. Outcome measures included wound healing rate, amputation-free survival (AFS), and freedom from reintervention. Propensity score matching was conducted to reduce baseline differences.</p><p><strong>Results: </strong>Propensity score matching extracted 69 pairs with no significant baseline differences. The wound healing rate was not significantly different between the angioplasty and nonangioplasty groups (64.0% vs 59.6%, <i>p</i> = 0.94). Similarly, no significant differences were observed in AFS (82.4% vs 82.2%, <i>p</i> = 0.94) and freedom from reintervention (51.1% vs 46.6%, <i>p</i> = 0.81). However, the lesion morphology at reintervention progressed from stenosis to occlusion more frequently in the angioplasty group than in the nonangioplasty group (39.3% vs 12.9%, <i>p</i> = 0.035). Multivariate analysis identified angioplasty in IM lesions as an independent predictor of lesion morphology progression in IM lesions.</p><p><strong>Conclusion: </strong>Angioplasty was associated with a higher rate of lesion morphology progression, which should be considered when determining treatment strategies.</p>","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"1358863X251361386"},"PeriodicalIF":3.3,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144837947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Images in Vascular Medicine: Aortocaval fistula between a persistent left superior vena cava and an area of aneurysmal degeneration after endovascular aortic repair.","authors":"Spyridon Prountzos, Nikolaos-Achilleas Arkoudis, Ornella Moschovaki-Zeiger, Sofoklis Antonakis, Stavros Spiliopoulos","doi":"10.1177/1358863X251363526","DOIUrl":"https://doi.org/10.1177/1358863X251363526","url":null,"abstract":"","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"1358863X251363526"},"PeriodicalIF":3.3,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144837948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vascular MedicinePub Date : 2025-08-06DOI: 10.1177/1358863X251363902
Woosup Michael Park, Sarah Budik, Alexander Malanowski, Hassan Aboumerhi, Leena Khaitan
{"title":"Vascular Disease Patient Information Page: Median arcuate ligament syndrome (MALS).","authors":"Woosup Michael Park, Sarah Budik, Alexander Malanowski, Hassan Aboumerhi, Leena Khaitan","doi":"10.1177/1358863X251363902","DOIUrl":"https://doi.org/10.1177/1358863X251363902","url":null,"abstract":"","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"1358863X251363902"},"PeriodicalIF":3.3,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144795654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vascular MedicinePub Date : 2025-08-05DOI: 10.1177/1358863X251346133
Rumi Faizer, Bo Claymore, Sarah Dike, David Dvorak, Camille Graham, Yauhen Tarbunou, Sue Duval
{"title":"Validation of transmetatarsal pressure as an alternative for evaluating severity of chronic limb-threatening ischemia.","authors":"Rumi Faizer, Bo Claymore, Sarah Dike, David Dvorak, Camille Graham, Yauhen Tarbunou, Sue Duval","doi":"10.1177/1358863X251346133","DOIUrl":"https://doi.org/10.1177/1358863X251346133","url":null,"abstract":"<p><p>IntroductionFew tests are validated for ischemia grading in chronic limb-threatening ischemia (CLTI). An additional, easily accessible and validated technique would be beneficial. This study aimed to determine whether transmetatarsal pressure (TMP) is valid in the evaluation of CLTI ischemia grade. We also aimed to assess if values for TMP were meaningful in patients with noncompressible ankle-brachial indices (ABI).MethodsA cohort of patients with peripheral artery disease (PAD) presenting to our vascular center from March 1 to May 1, 2022, underwent TMP measurement concurrent with ABI and toe pressure (TP) measurement. Linear and quadratic regression models were used to assess the relation between TMP and TP or ABI.ResultsA total of 108 patients who were being followed for PAD underwent testing. Half had a history of CLTI (55% of patients with diabetes and 43% of patients without diabetes). The relation between TP and TMP was best described by a quadratic formula with an <i>R</i><sup>2</sup> value of 0.41. By combining the existing WIfI ischemia ranges defined by TP and the quadratic formula, new ischemia grades were calculated for TMP. Ischemia grades 0, 1, 2, and 3 corresponded to ranges of TMP pressure (mmHg) of ≥ 75, 45-74, 30-44, and < 30. There were 25 instances where a patient had an abnormally elevated ABI. None of these patients had a noncompressible TP or TMP.ConclusionWe demonstrated that TMP can be integrated into the WIfI classification. We believe that TMP evaluation may increase the reliability, accuracy, and accessibility of CLTI assessment and management.</p>","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"1358863X251346133"},"PeriodicalIF":3.3,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144790167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vascular MedicinePub Date : 2025-08-01Epub Date: 2025-05-26DOI: 10.1177/1358863X251333932
Firas Hentati, Brett J Carroll, Timothy P Murphy, Madeleine R Murphy, Eric A Secemsky
{"title":"Identifying predictors of durable treatment response among patients with claudication: A secondary analysis of the CLEVER trial.","authors":"Firas Hentati, Brett J Carroll, Timothy P Murphy, Madeleine R Murphy, Eric A Secemsky","doi":"10.1177/1358863X251333932","DOIUrl":"10.1177/1358863X251333932","url":null,"abstract":"<p><strong>Background: </strong>Symptomatic peripheral artery disease (PAD) is prevalent and guideline-recommended therapies include optimal medical therapy (OMT), supervised exercise therapy (SET), and revascularization (stenting). The Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) trial examined longitudinal patient-reported outcomes to assess response to OMT, SET, and stenting. The predictors of symptomatic improvement have not been fully assessed.</p><p><strong>Methods: </strong>This is a secondary analysis of the CLEVER trial, which randomized patients with claudication to OMT alone, OMT plus SET, or OMT plus stenting. The primary outcome was a change in the Peripheral Artery Questionnaire (PAQ) summary score by 10 points or more from baseline to 6 and 18 months. Multivariate logistic regression was used to identify predictors of response.</p><p><strong>Results: </strong>Of the 103 participants (66 men, median age 63 years), 65 (63%) had a response to therapy at 6 months. Of 98 participants who completed the 18-month PAQ, 52 (53%) had a symptomatic response. On binary logistic regression, when compared to OMT, SET (6 months: odds ratio [OR] 4.25, 95% CI: 1.33-13.58; 18 months: OR 3.92, 95% CI: 1.04-14.70) and ST (6 months: OR 5.19, 95% CI: 1.58-17.03; 18 months: OR 11.50, 95% CI: 2.89-45.72) were associated with an increase in PAQ at 6 and 18 months.</p><p><strong>Conclusion: </strong>Among randomized patients in the CLEVER trial, treatment with either SET or stenting was predictive of clinically meaningful change in the PAQ summary score from baseline to 6 and 18 months. These interventions, with a prioritization of SET, should be more widely available to patients with PAD. This study adds to the findings of the CLEVER trial by denoting that SET and stenting are beneficial in patients with PAD, independent of comorbidities.</p>","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"431-438"},"PeriodicalIF":3.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vascular MedicinePub Date : 2025-08-01Epub Date: 2025-05-14DOI: 10.1177/1358863X251334141
Haley Schachter, Julie Blaszczak, Geoffrey D Barnes
{"title":"Review of venous thromboembolism (VTE) risk, evaluation, and treatment in individuals on estrogen-based gender-affirming hormone therapy.","authors":"Haley Schachter, Julie Blaszczak, Geoffrey D Barnes","doi":"10.1177/1358863X251334141","DOIUrl":"10.1177/1358863X251334141","url":null,"abstract":"<p><p>Epidemiological studies of transgender women suggest that these individuals experience higher rates of venous thromboembolism than their cisgender peers. Several factors likely increase this risk, including medication use, comorbidities, and social determinants of health. Estrogen-based gender-affirming hormone therapy is critical for helping patients address unwanted secondary sexual characteristics and induce physical changes in accordance with their gender identity. However, the use of estrogen-based gender-affirming hormone therapy may increase the risk of venous thromboembolism. This review article summarizes the current evidence describing venous thromboembolism risk among patients using various forms of estrogen, including transgender and cisgender individuals. The article also discusses strategies for managing venous thromboembolism in patients using estrogen-based gender-affirming hormone therapy and methods to reduce venous thromboembolism risk.</p>","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"488-498"},"PeriodicalIF":3.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vascular MedicinePub Date : 2025-08-01Epub Date: 2025-05-23DOI: 10.1177/1358863X251322179
Duc M Giao, Alex M Poluha, Eric A Secemsky, Anna K Krawisz
{"title":"Endovascular renal denervation for the treatment of hypertension.","authors":"Duc M Giao, Alex M Poluha, Eric A Secemsky, Anna K Krawisz","doi":"10.1177/1358863X251322179","DOIUrl":"10.1177/1358863X251322179","url":null,"abstract":"<p><p>Endovascular renal denervation (RDN) is a catheter-based, procedural therapy for the treatment of hypertension that was approved by the US Food and Drug Administration (FDA) in November 2023. Early studies suggest that endovascular RDN reduces blood pressure (BP) in patients with hypertension. However, BP response to RDN is highly variable, optimal patient selection remains uncertain, and the procedure's high cost remains a significant challenge. The purpose of this review is to comprehensively examine the literature regarding the mechanism by which endovascular RDN reduces BP and the safety and effectiveness of RDN, and to discuss key considerations for selecting appropriate patients for endovascular RDN. Relevant studies in the field were identified from PubMed using search terms including 'renal denervation' and 'renal denervation for hypertension.' In conclusion, clinical trials have demonstrated a statistically significant BP-lowering effect of endovascular RDN, which based on multiple trials with long-term follow-up, appears to persist over several years with low complication rates. More research is needed to understand which patients benefit most from endovascular RDN and to evaluate the long-term outcomes, including the impact of endovascular RDN on cardiovascular events.</p>","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"499-509"},"PeriodicalIF":3.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vascular MedicinePub Date : 2025-08-01Epub Date: 2025-07-17DOI: 10.1177/1358863X251353771
Robert T Eberhardt, Maria Teresa Abola, Eri Fukaya, Tapas Ghose, Kamal Gupta, Naomi Hamburg, R Kevin Rogers, Bryan J Wells
{"title":"Funding for vascular medicine fellowships: Learning from the past and planning for the future.","authors":"Robert T Eberhardt, Maria Teresa Abola, Eri Fukaya, Tapas Ghose, Kamal Gupta, Naomi Hamburg, R Kevin Rogers, Bryan J Wells","doi":"10.1177/1358863X251353771","DOIUrl":"10.1177/1358863X251353771","url":null,"abstract":"","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"530-533"},"PeriodicalIF":3.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144650699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Sex-based difference in functional performance and quality of life 1 year after supervised exercise training in patients with symptomatic peripheral artery disease.","authors":"Stefano Lanzi, Anina Pousaz, Luca Calanca, Lucia Mazzolai","doi":"10.1177/1358863X251322394","DOIUrl":"10.1177/1358863X251322394","url":null,"abstract":"<p><strong>Introduction: </strong>The long-term effects of supervised exercise training (SET) on functional performance and health-related quality of life (HRQoL) in symptomatic peripheral artery disease (PAD) are poorly investigated, especially in women. This study investigated these outcomes 1 year after SET in both women and men.</p><p><strong>Methods: </strong>In this single-arm, prospective, nonrandomized study, patients with symptomatic PAD participating in the 3-month SET program were investigated. Functional performance (6-minute walking distance [6MWD], the stair-climbing test [SCT], and the short physical performance battery [SPPB]), and HRQoL (physical component summary [PCS] score of the Short Form-36 questionnaire) were assessed before and following SET, as well as at 6 and 12 months after SET completion.</p><p><strong>Results: </strong>Ninety patients (women: <i>n</i> = 30; men: <i>n</i> = 60) with chronic symptomatic PAD (ankle-brachial index 0.78 ± 0.22; mean age 65.4 ± 10.2 years) were included in the study. The 6MWD (<i>women</i>: before: 387.2 ± 88.6 m; after: 472.4 ± 57.0 m; 12 months: 469.9 ± 57.8 m; <i>men</i>: before: 431.7 ± 94.0 m; after: 477.5 ± 88.6 m; 12 months: 467.2 ± 73.4 m), SPPB score (<i>women</i>: before: 9.6 ± 2.4; after: 11.3 ± 1.0; 12 months: 11.2 ± 0.5; <i>men</i>: before: 10.6 ± 1.4; after: 11.5 ± 0.9; 12 months: 11.3 ± 0.8), and SCT (<i>women</i>: before: 8.6 ± 4.4 s; after: 5.6 ± 1.6 s; 12 months: 5.8 ± 1.2 s; <i>men</i>: before: 6.2 ± 2.3 s; after: 5.0 ± 1.9 s; 12 months: 5.3 ± 1.6 s) significantly improved over time (<i>p</i> ≤ 0.001), with no significant differences between women and men. The PCS score (<i>women</i>: before: 30.3 ± 8.0; after: 38.8 ± 8.4; 12 months: 35.7 ± 7.4; <i>men</i>: before: 32.4 ± 10.5; after: 35.7 ± 9.5; 12 months: 35.4 ± 7.6) significantly improved in women only (<i>p</i> = 0.020).</p><p><strong>Conclusion: </strong>One year after SET, both women and men with PAD exhibit similar functional benefits, whereas HRQoL improvements were observed exclusively in women.</p>","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"423-430"},"PeriodicalIF":3.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144053494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}